Form 4 for HAE HAEMONETICS CORP
Accepted 2022-05-18 00:00:00 ET · period of report 2022-05-16 · accession 0001127602-22-014984 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-18 | 2022-05-16 | HAE | Lingamneni Anila | EVP, CTO | A - Grant | — | +4,340 | 18.7K | +30% | — |
| D | 2022-05-18 | 2022-05-16 | HAE | Lingamneni Anila | EVP, CTO | A - Grant | $0.00 | +10.1K | 10.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-16 | A | A | 4,340 | — | 18,706 | D | — | — | (F1) The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. (F2) Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. (F3) This number includes unvested RSUs previously reported as well as 353 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 29, 2022. |
| 2 | Derivative | Non-qualified Stock Option (Right to Buy) | 2022-05-16 | A | A | 10,148 | $0.00 | 10,148 | D | $57.60 · — to 2029-05-16 | 10,148 Common Stock | (F4) Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. |